JPH02103203A - Purification of hyaluronic acid - Google Patents
Purification of hyaluronic acidInfo
- Publication number
- JPH02103203A JPH02103203A JP25498588A JP25498588A JPH02103203A JP H02103203 A JPH02103203 A JP H02103203A JP 25498588 A JP25498588 A JP 25498588A JP 25498588 A JP25498588 A JP 25498588A JP H02103203 A JPH02103203 A JP H02103203A
- Authority
- JP
- Japan
- Prior art keywords
- hyaluronic acid
- ethanol
- solution
- water
- organic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 33
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 31
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 31
- 238000000746 purification Methods 0.000 title description 3
- 239000003960 organic solvent Substances 0.000 claims abstract description 10
- 239000007864 aqueous solution Substances 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 38
- 239000000243 solution Substances 0.000 abstract description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 7
- 238000000855 fermentation Methods 0.000 description 7
- 230000004151 fermentation Effects 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000194048 Streptococcus equi Species 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
- 229940099552 hyaluronan Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 230000001698 pyrogenic effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000008394 flocculating agent Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- -1 propatool Chemical compound 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発ＢＡはヒアルロン酸含有液からヒアルロン酸を分離
・精製する方法に関する。ヒアルロン酸は化粧品の保湿
剤の他、眼科、整形外科、皮膚科等で医薬品としての用
途が開かれてきている。DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present BA relates to a method for separating and purifying hyaluronic acid from a hyaluronic acid-containing liquid. In addition to cosmetic moisturizing agents, hyaluronic acid is also being used as a pharmaceutical in ophthalmology, orthopedics, dermatology, and other fields.
従来、ヒアルロン酸は、動物組織、例えば、工業規模で
は、ニワトリのトサカ等からの抽出法により製造されて
いるが、夾雑物としてコンドロイチン硫酸が混入したシ
、組織内に含まれるヒアルロニダーゼなどによって低分
子量化されやすい、従って高分子で高純度に精製された
ものは、コスト高になる。Conventionally, hyaluronic acid has been produced by extraction from animal tissues, such as chicken combs on an industrial scale, but it has a low molecular weight due to contaminants such as chondroitin sulfate and hyaluronidase contained in the tissue. Therefore, polymers that are highly purified are expensive.
これら問題点ｔ−解決するため、近年醗酵法にょシヒフ
ルＨ７酸を製造することが行なわれている。In order to solve these problems, in recent years fermentation methods have been used to produce H7 acid.
ヒアルロン酸がストレプトコツカス属のある群のバクテ
リアにより生産されることは、古くから知られ、多くの
報告がある（ゾエービー ウールコック（Ｊ、Ｂ、 Ｗ
ｏｏｌｃｏｃｋ ） 、シャ〜ナルーオグーゾエネラル
マイクロパイオロゾイ ８５ ３７２−５７５ １９７
６）。It has been known for a long time that hyaluronic acid is produced by a group of bacteria of the genus Streptococcus, and there are many reports (Zoeby Woolcock (J, B, W).
oolcock), Sha-Naru Oguzo Eneral Micropiorozoi 85 372-575 197
6).
醗酵法によって製造されるヒアルロンｃＲは、抽出法に
比べ、一定の原料で、一定の方法で製造されるため、製
品の品質が一定に保たれることから、産業上の利用価値
は大きい。Compared to the extraction method, hyaluronic cR produced by the fermentation method is produced using a fixed raw material and a fixed method, so the quality of the product is kept constant, and therefore has great industrial utility value.
しかしながら、醗酵液には、高分子化金物が不純物とし
て存在し、それらを分Ｗ／ｉ除去してＩ！６純度の製品
を得る方法が検討されてきた。However, polymerized metals are present as impurities in the fermentation liquid, and these are removed by I! Methods to obtain 6-purity products have been investigated.
例えば、本発明者らも先にアルミナを用いて発熱性物質
、タンパク質等を除去するヒアルロン酸の精製法を提案
した（％願昭６３−１４４７２８号明細誉）。For example, the present inventors have previously proposed a method for purifying hyaluronic acid using alumina to remove pyrogens, proteins, etc. (Patent Application No. 144728/1983).
このアルミナを用いた方法も含め従来のｍ展処理方法嬬
、いずれもζアルロン酸を水溶液の状態で精製処理を行
なう方法であった。このような方法を用いた場合、原料
の違い等によシ発熱性物質、タンパク質等が十分に除去
されず、安定したｉｉ＆：云効果が得られない場合が多
（、実用上問題を残しており、医薬品として使用できる
高品質な製品を再現性よく、安定して得る方法の開発が
待たれていた。All conventional m-extension treatment methods, including this method using alumina, involve purifying ζ-aluronic acid in the form of an aqueous solution. When such methods are used, pyrogenic substances, proteins, etc. are not sufficiently removed due to differences in raw materials, and stable effects cannot be obtained in many cases. Therefore, the development of a method to reproducibly and stably obtain high-quality products that can be used as pharmaceuticals has been awaited.
本発明は簡便かつ高品質なヒアルロンｇＩＩを再棉性よ
く分離・積装する方＠を提供することを目的としている
。The object of the present invention is to provide a simple method for separating and loading high-quality hyaluron gII with good recyclability.
タンパク質、核酸、金属等の不純物を効率よく、しかも
再現性よく分ｌＩｉ除去し、高純度、かつ構製過程で低
分子化が起こりにくい精製方法について、鋭意検討した
結果、ヒアルロン酸を、精製する際に、その一部又は全
工程を水と混和する有機溶剤を用いて行なうことで、安
定して発熱性物質等の不純物を除去し、その目的が達せ
られる事を見出し、本発明を完成するに到った。As a result of extensive research into a purification method that efficiently and reproducibly removes impurities such as proteins, nucleic acids, and metals, resulting in high purity and resistant to lower molecular weight during the construction process, we have purified hyaluronic acid. In this process, they discovered that by performing some or all of the steps using an organic solvent that is miscible with water, impurities such as pyrogenic substances can be stably removed and the objective can be achieved, and the present invention has been completed. reached.
すなわち本発明は、ヒアルロン酸含有液を水と混和する
有機溶剤の水溶液で処理することを特徴とするヒアルロ
ン酸の＠＃！法である。That is, the present invention is characterized in that a hyaluronic acid-containing liquid is treated with an aqueous solution of an organic solvent that is miscible with water. It is the law.
本発明で用いられる有４ＩＡ溶剤は、メタノール、エタ
ノール、プロパツールといったアルコール類、アセトン
といり九本と混和する有機溶剤ならば特に種類を問わな
いが、グレードとしては試薬グレードのものを使用する
ことが好ましい。本発明は、有機溶剤をとアルロン戚含
有水溶液に加えたり、ま九、所定濃度の古本有機溶剤に
ヒアルロン［’に溶解して精製処理を行なうことｔ−特
徴とする。この時の加える有機溶剤の濃度は、ヒアルロ
ン酸が析出しない程度の濃度までの広い濃度範囲で使用
できる。The type of 4IA solvent used in the present invention is not particularly limited as long as it is an organic solvent that is miscible with alcohols such as methanol, ethanol, propatool, and acetone, but it is recommended to use a reagent grade solvent. is preferred. The present invention is characterized in that hyaluronic acid is purified by adding an organic solvent to an aqueous solution containing hyaluronan, or by dissolving hyaluronic acid in an organic solvent of a predetermined concentration. The concentration of the organic solvent added at this time can be used within a wide concentration range up to a concentration that does not precipitate hyaluronic acid.
しかしながら、最も安定した効果を得るには２０〜５〇
−程度の範囲が好ましい。However, in order to obtain the most stable effect, a range of about 20 to 50 is preferable.
本発明で使用するヒアルロン酸含有液は動物組織から抽
出したものでも、又醗酵法で製造したものでも使用する
ことはできるが工業的に安価に、高品質な製品を安定に
製造するためには醗酵法で製造したものが望ましい。The hyaluronic acid-containing liquid used in the present invention can be extracted from animal tissues or manufactured by fermentation, but in order to stably manufacture high-quality products at industrially low cost, It is preferable to use fermentation method.
醗酵法によるヒアルロン酸はストレプトコッカス属等の
バクテリアを使用して既知の方法で得ることができる。Hyaluronic acid produced by fermentation can be obtained by known methods using bacteria such as Streptococcus.
醗酵法で使用する菌株は、自然界から分離されるストレ
プトコツカス属等のヒアル党ン酸生産能を有する微生物
、また鉱、特開昭６３−１２５５９２号公報に記したス
トレプトコッカス・エキＩＦＭ−１００（倣工研菌寄第
９０２７号）のような高収率で安定にζアルクンｆＲｔ
生産する変異株が好まし一〇
そのようなヒアルロン酸生産能を有する微生物ヲクルコ
ース、シェークロース等の炭素源、ペゾトン、ポリペプ
トン、酵母エキス等の窒Ｘ源、ビタミン、無機塩等を用
いた培地中で好気的に培養して得られる培養液をヒアル
ロン酸が０．１〜５Ｉ／！濃度になるように希釈後、既
知の方法、例えは遠心分離による除菌、濾過による除菌
、凝集剤による除菌、カーボン、セライト等による除菌
などの方法で除菌した液を使用することが望ましい。Bacterial strains used in the fermentation method include microorganisms that have the ability to produce hyaluronan acid, such as Streptococcus spp. isolated from nature, and Streptococcus equi IFM-100 (described in JP-A-63-125592) High-yield and stable ζ-alkun fRt such as Imitation Koken Bacterial Serial No. 9027)
Preferably, the mutant strain that produces such a microorganism having the ability to produce hyaluronic acid is used in a medium containing a carbon source such as Woclucose or Shakerose, a nitrogen X source such as pezoton, polypeptone, or yeast extract, vitamins, inorganic salts, etc. Hyaluronic acid is 0.1 to 5 I/! After diluting to a certain concentration, use a solution that has been sterilized by known methods, such as sterilization by centrifugation, filtration, sterilization by flocculants, sterilization by carbon, celite, etc. is desirable.
さらに望ましくは、透析処理による低分子化金物の除去
、精密濾過処理による水不溶微粒子の除去、またヒアル
ロン酸含有液にアルコール、アセトン、ジオキサンなど
の水溶性有機溶剤を添加してヒアルロンＩ！を析出分ｌ
１１１ｉ後、再度０．１〜５．Ｆ／ｌ濃度にヒアルロン
酸を溶解して使用することである。More preferably, dialysis treatment is used to remove low-molecular weight metals, precision filtration treatment is used to remove water-insoluble particles, and a water-soluble organic solvent such as alcohol, acetone, or dioxane is added to the hyaluronic acid-containing solution to obtain Hyaluronic I! The precipitated fraction l
After 111i, 0.1 to 5. Hyaluronic acid is dissolved in F/l concentration and used.
本発明における１ＩＩＩ裂処理方法としては、有機浴剤
含有液を用いて行なえるＷＩ製処理方法ならば何でも良
く限定されることはないが、アルミナや活性炭、７ａｊ
Ｊゾルを用いた処理方法では特に安定した効果が得られ
る。The method for treating 1III cracks in the present invention is not limited to any method as long as it is a WI treatment method that can be carried out using a liquid containing an organic bath agent.
Particularly stable effects can be obtained with the treatment method using J-sol.
ここで用いられるアルミナ、活性炭、フロリシルは、従
来の精１１１１Ｍ理法で用いられるもので、そのｌｉｄ
、形状等は特に限定されることはない。また地理の方法
としては、ヒアルロン酸含有液にこれらを粉状又は粒状
で添加攪拌するバッチ式と充填塔等に粒状又鉱成戯した
ものを充填後、ヒアルロン酸含有液を通液処理方法、ま
たその組合せや反復も可能であるが、バッチ式に比べて
、光槙塔方式の方が効果的である。またこの時の−は６
〜８が望ましく、ＧＶは０．１〜０．２が最も効果的で
ある。The alumina, activated carbon, and Florisil used here are those used in the conventional Sei 1111M process, and the lid
, shape, etc. are not particularly limited. Geography methods include a batch method in which powder or granules are added to a hyaluronic acid-containing solution and stirred, and a method in which the granular or mineralized product is filled into a packed tower or the like, and then the hyaluronic acid-containing solution is passed through the solution. Combinations and repetitions are also possible, but the light tower method is more effective than the batch method. Also, - at this time is 6
-8 is desirable, and GV of 0.1-0.2 is most effective.
次に本発明の実施例を示す。 Next, examples of the present invention will be shown.
参考例（ブランク）
ストレプトコッカス・エクイＩＦＭ−１００（倣工研菌
寄第９０２７号）を用いて培養した培養液１５１’ｆｒ
Ｈ水で５０１に希釈しくヒフルロンＩＲ磯度１．１０．
＠／ノ）、遠心分離、ホローファイバー型限外ろ過を行
ない、菌体と培地成分を除いた。Reference example (blank) Culture solution 151'fr cultured using Streptococcus equi IFM-100 (Imitation Koken Bacteria No. 9027)
Diluted with H water to a concentration of 1.10.
@/ノ), centrifugation, and hollow fiber ultrafiltration were performed to remove bacterial cells and medium components.
このヒアルロン酸含有液５００ｄに食塩１５．Ｆを溶解
、−７に胸Ｍ５後、エタノール７５０Ｍで析出、エタノ
ール１００ｄで洗浄を行い、４０℃で真空乾燥し、０．
４９．９のヒアルロン酸ナトリウムを得た。分析結果を
表１に示した。Add 500 d of this hyaluronic acid-containing liquid to 15 ml of salt. F was dissolved, and after M5 at -7, it was precipitated with 750M ethanol, washed with 100M ethanol, dried under vacuum at 40°C, and dried at 40°C.
49.9 of sodium hyaluronate was obtained. The analysis results are shown in Table 1.
実施例１
参考例で得られた粗精製ヒアルロンＭ、ｔ−１，０，９
と９．水７００Ｍに溶解した後、エタノール３００ａを
加えて０．１チヒアルロン酸工タノール混合溶液とした
。Example 1 Crude purified Hyaluron M obtained in Reference Example, t-1,0,9
and 9. After dissolving in 700M of water, 300a of ethanol was added to obtain a 0.1% hyaluronic acid-tanol mixed solution.
一方、内径１１．６α高さ１５ａｎのカラムに、昭ノ々
（６０ゴ／時）で通液した、カラム通過液を５００４と
９食ｆｆ１１ ！Ｍを加え、エタノール７５ｏＩＬｌで
析出・乾燥して、０．４＆のヒアルロン酸ナトリウムを
得た。分析結果を表１に示した。同一の操作を１０回行
なったが、結果はすべて表１に示した値であった。On the other hand, the column-passing liquid, which was passed through a column with an inner diameter of 11.6α and a height of 15 ant at a rate of 60 g/hr, was 5004 and 9 servings ff11! M was added, and the mixture was precipitated and dried with 750ml of ethanol to obtain 0.4&ml of sodium hyaluronate. The analysis results are shown in Table 1. The same operation was performed 10 times, and all the results were the values shown in Table 1.
比較例１
実施例１で、エタノールを水にかえた以外はく但し、析
出用エタノールは使用する〕、同様の操作を行なった。Comparative Example 1 The same operation as in Example 1 was carried out except that ethanol was replaced with water, but ethanol for precipitation was used.
この操作ｔ−１０回行ない分析結果の平均値を示した。This operation was performed t-10 times and the average value of the analysis results is shown.
表 １
比較例１では、実施例１と同等の品質のヒアルロン酸の
得られる場合もめったが、再現性がなく、平均すると表
１に示す結果となった。Table 1 In Comparative Example 1, hyaluronic acid of the same quality as in Example 1 was rarely obtained, but it was not reproducible, and the average results were as shown in Table 1.
実施例２
実施例１でエタノールをアセトンにかえた以外は（但し
、析出用エタノールは使用する）同様に行なった。Example 2 The same procedure as in Example 1 was carried out except that ethanol was replaced with acetone (however, ethanol for precipitation was used).
実施例３
参考例の粗ｍ製ヒアルロン酸を０．１ ！Ｉとシ水７Ｑ
ａ＋７に溶解した後、エタノール６０ゴを加えて０．１
％ヒアルロン酸エタノール混甘せ液とした。Example 3 0.1 of the crude hyaluronic acid of the reference example! I and Shimizu 7Q
After dissolving in a+7, add 60 g of ethanol and make 0.1
% hyaluronic acid mixed with ethanol.
これに食塩６ｇを加えた後、活性Ｒ（和光社製、特級）
０．１ ／ ｔ−加え３Ｕ’Ｃ１ｈｒ攪拌した。その
後、０．２μフイルター処理を行なった後、１．５倍量
のエタノールを加えて析出させた〇析出したヒアルロン
酸の分析結果を表３に示した。同一の操作ｔ１０回行な
ったが、結果はすべて表６に示した値であり九。After adding 6g of salt to this, Active R (manufactured by Wakosha, special grade)
0.1/t- was added and stirred for 3 U'C1 hr. Thereafter, after treatment with a 0.2 μ filter, 1.5 times the amount of ethanol was added to precipitate it. Table 3 shows the analysis results of the precipitated hyaluronic acid. The same operation was performed t10 times, and all the results were the values shown in Table 6.
比較例２
実施例６でエタノールを水にかえた以外は（但し析出用
エタノールは使用する）同様の操作を１０回行なった。Comparative Example 2 The same operation as in Example 6 was performed 10 times except that ethanol was replaced with water (however, ethanol for precipitation was used).
その結果の平均値を比較例２とした。The average value of the results was defined as Comparative Example 2.
畳 比較例１の値を示した。Tatami: Values for Comparative Example 1 are shown.
表 １０回行なった。その結果の平均値を比較例６とした。table I did it 10 times. The average value of the results was defined as Comparative Example 6.
実施例４
参考例の粗精製ヒアルロン酸を０．２Ｉとシ水１４０−
に溶解した後、エタノール６０ａを加え、これに食塩を
１２．ｆ？Ｉ肩させ丸。この溶液ｔ−１５ｇの６０−１
００メツシユの７ｏリシルを光横したカラム（直径１．
５ｃｍ）に５ｖ＝ｉで通液した。Example 4 The crudely purified hyaluronic acid of the reference example was mixed with 0.2I and water 140-
After dissolving in the solution, add ethanol 60a, and add salt to this for 12. f? I Shoulder Sase Maru. 60-1 of this solution t-15g
A column (diameter 1.
5cm) at 5v=i.
この溶液に１．５倍量エタノールを加えて析出させ、析
出したヒアルロン酸の分析結果を表４に示した。同一の
操作を１０回行なりたが結果はｔぺて表４に示した値で
あった。1.5 times the amount of ethanol was added to this solution to precipitate it, and the analysis results of the precipitated hyaluronic acid are shown in Table 4. The same operation was performed 10 times, and the results were as shown in Table 4.
比較例３
実施例４でエタノールを水にかえた以外はく但し、析出
用エタノールは使用する〕同様の操作を測定法
１ン蛋白質含ｔ：精製とアルΩ７歳を％０．ＩＮ水酸化
ナトリウムに溶解し、
ローリ−法にて行なった。Comparative Example 3 [Example 4 except that ethanol was replaced with water, but the ethanol for precipitation was used] The same procedure was carried out as the method for measuring 1 protein content: purification and alcohol 7 years old. It was dissolved in IN sodium hydroxide and carried out by the Lowry method.
２）核 ＃ ：０．１９６ヒアルロン酸ナトリウム
溶液の２６０ ｎｍにおける吸
光度を測定した。2) Nucleus #: The absorbance of a 0.196 sodium hyaluronate solution at 260 nm was measured.
６）発熱性物質：生化学工業社製トキシカラーシステム
によｐ比色分析する
ことによシ行なった。6) Pyrogenic substance: This was carried out by colorimetric analysis using a Toxicolor system manufactured by Seikagaku Corporation.
本発明によれば、高品質なとアルキン酸を安定して得る
ことができる。またこの方法で得られたヒアルロン酸は
医薬方面の用途が期待される。According to the present invention, high quality alkyl acids can be stably obtained. Furthermore, the hyaluronic acid obtained by this method is expected to have medical uses.
ｑ＃奸出出願 人気化学工業株式会社q# Unauthorized application Niki Kagaku Kogyo Co., Ltd.
Claims (1)
で処理することを特徴とするヒアルロン酸の精製法。A method for purifying hyaluronic acid, which comprises treating a hyaluronic acid-containing liquid with an aqueous solution of an organic solvent that is miscible with water.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63254985A JP2938880B2 (en) | 1988-10-12 | 1988-10-12 | Purification method of hyaluronic acid |
| US07/347,337 US4946780A (en) | 1988-10-12 | 1989-05-04 | Method for producing sodium hyaluronate by fermentation method |
| DE68914236T DE68914236T2 (en) | 1988-10-12 | 1989-05-11 | Process for the production of sodium hyaluronate by fermentation. |
| EP89108522A EP0363561B1 (en) | 1988-10-12 | 1989-05-11 | Method for producing sodium hyaluronate by fermentation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63254985A JP2938880B2 (en) | 1988-10-12 | 1988-10-12 | Purification method of hyaluronic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH02103203A true JPH02103203A (en) | 1990-04-16 |
| JP2938880B2 JP2938880B2 (en) | 1999-08-25 |
Family
ID=17272608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63254985A Expired - Lifetime JP2938880B2 (en) | 1988-10-12 | 1988-10-12 | Purification method of hyaluronic acid |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2938880B2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006104461A (en) * | 2004-09-10 | 2006-04-20 | Seikagaku Kogyo Co Ltd | Method for removing impurity in glycosaminoglycan fraction |
| US7575914B2 (en) | 2002-08-19 | 2009-08-18 | Kolon Life Science, Inc. | Microorganism producing hyaluronic acid and purification method of hyaluronic acid |
| JPWO2007142285A1 (en) * | 2006-06-07 | 2009-10-29 | 協和発酵バイオ株式会社 | Purification method of hyaluronate |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60133894A (en) * | 1983-11-25 | 1985-07-17 | マイルス・ラボラトリース・インコーポレーテツド | Hyaruronic acid and its production |
-
1988
- 1988-10-12 JP JP63254985A patent/JP2938880B2/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60133894A (en) * | 1983-11-25 | 1985-07-17 | マイルス・ラボラトリース・インコーポレーテツド | Hyaruronic acid and its production |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7575914B2 (en) | 2002-08-19 | 2009-08-18 | Kolon Life Science, Inc. | Microorganism producing hyaluronic acid and purification method of hyaluronic acid |
| JP2006104461A (en) * | 2004-09-10 | 2006-04-20 | Seikagaku Kogyo Co Ltd | Method for removing impurity in glycosaminoglycan fraction |
| JPWO2007142285A1 (en) * | 2006-06-07 | 2009-10-29 | 協和発酵バイオ株式会社 | Purification method of hyaluronate |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2938880B2 (en) | 1999-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI79346C (en) | FRAMSTAELLNING AV HYALURONSYRA MEDELST BAKTERIEKULTUR. | |
| EP0340628B1 (en) | Sulfoamino derivatives of chondroitin sulfates, of dermaten sulfate and of hyaluronic acid and their pharmacological properties | |
| JP3081544B2 (en) | High molecular weight sodium hyaluronate composition | |
| JP2677553B2 (en) | Method for producing high molecular weight sodium hyaluronate by fermentation of streptococcus | |
| KR101509139B1 (en) | Method for purifying hyaluronic acid | |
| DE69828193T2 (en) | HYALURONAN SYNTHASE GENE AND ITS USE | |
| JP2010521972A (en) | A shortened purification process for the production of capsular Streptococcus pneumoniae polysaccharides | |
| JPH09324001A (en) | Purification method for sodium hyaluronate | |
| FR2478646A2 (en) | MUCOPOLYSACCHARIDIC COMPOSITION HAVING A COAGULATION REGULATING ACTIVITY, MEDICAMENT CONTAINING THE SAME, AND METHOD FOR OBTAINING THE SAME | |
| JPH04158796A (en) | Production of aqueous solution of sodium hyaluronate | |
| EP0694616A2 (en) | Process for the preparation of hyaluronic acid by fermentation with streptococcus | |
| JP2020507666A (en) | Decomposition method of polysaccharide using ozone | |
| CA2360343C (en) | Process for purifying high molecular weight hyaluronic acid | |
| CN1916030B (en) | Highly sulfated derivatives of k5 polysaccharide and their preparation | |
| US20060127987A1 (en) | Microorganism producing hyaluronic acid and purification method of hyaluronic acid | |
| JPH02103203A (en) | Purification of hyaluronic acid | |
| US5493015A (en) | Method for reducing contaminative live bacteria in xanthan gum | |
| JP5603926B2 (en) | Hyaluronic acid purification method and production method | |
| JPS6279790A (en) | Production of modified hyaluronic acid | |
| JP2594322B2 (en) | Purification method of hyaluronic acid | |
| KR0149793B1 (en) | Purification method of high molecular hydraulic acid | |
| JP2731545B2 (en) | Method for purifying hyaluronic acid | |
| EP0346467A1 (en) | Process for purifying hyaluronic acid | |
| KR100829086B1 (en) | Purification method of hyaluronic acid or salt thereof | |
| KR20110056346A (en) | Processing for medical hylaronic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090611 Year of fee payment: 10 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090611 Year of fee payment: 10 |